Replimune Group Q2 2026 Results: Net Loss of $57.1M, Loss Narrows
Replimune Group, Inc. reported a net loss of $126.9 million for the six months ended September 30, 2026, an improvement from the $169.8 million loss in the prior year period. The company significantly strengthened its cash position to $307.8 million through the issuance of common stock and pre-funded warrants, while transitioning to a commercial-stage biotechnology company.
- Key figure
- Net loss $57.1M